Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...
The Michael Almereyda and Courtney Stephens movie, narrated by Chloë Sevigny and premiering at the Rotterdam film festival, explores the life of the utopian neuroscientist who developed the isolation ...
Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and with caution. As the creator of the blockbuster weight-loss drug Zepbound, and ...
Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American ...
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
This is an audio transcript of the FT News Briefing podcast episode: ‘Trump steers the world towards a tax war’ Sonja Hutson Good morning from the Financial Times. Today is Friday, January 24th. And ...
Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.